The quality of life associated with prophylactic treatments for women with BRCA1/2 mutations

Cancer Journal from Scientific American

Volumn 5, Issue 5, 1999, Pages 283-292

  Grann, Victor R ^a,b   Jacobson, Judith S ^a   Sundararajan, Vijaya ^a   Albert, Steven M ^a   Troxel, Andrea B ^a   Neugut, Alfred I ^a  

^a Columbia University ^*  (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

BRCA1; BRCA2; Breast cancer; Chemoprevention; Ovarian cancer; Prophylactic surgery; Quality of life

Indexed keywords

TAMOXIFEN;

ADULT; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER GENETICS; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC RISK; HEALTH STATUS; HIGH RISK POPULATION; HUMAN; MASTECTOMY; ONCOGENE; OVARIECTOMY; OVARY CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE;

ADULT; BRCA2 PROTEIN; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COST-BENEFIT ANALYSIS; DECISION MAKING; FAMILY HEALTH; FEMALE; GENES, BRCA1; HETEROZYGOTE; HUMANS; LIFE EXPECTANCY; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PRIMARY PREVENTION; QUALITY OF LIFE; QUESTIONNAIRES; RISK FACTORS; TRANSCRIPTION FACTORS;

EID: 0032820774     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Grann VR, Panageas KS, Whang W et al. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol 1998;16:979-985.
2. Schrag D, Kuntz KM, Garber JE et al. Decision analysis: effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997;336:1464-1471.
3. Tamoxifen for early breast cancer: an overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351:1451-1467.
4. New hope for prevention, treatment of breast cancer. Harv Health Lett 1998;23:6-7.
5. Cummings S, Norton L, Eckert S et al. Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in postmenopausal women. Proc ASCO 1998;17:3.
6. Narod SA, Risch H, Moslehi R et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998;339:424-428.
7. Bayley KB, London MR, Grunkemeier GL et al. Measuring the success of treatment in patient terms. Med Care 1995;33:AS226-235.
8. Cella DF, Tulsky DS, Gray G et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993;11:570-579.
9. Russell LB, Gold MR, Siegel JE et al. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996;276:1172-1177.
10. Torrance GW. Utility approach to measuring health-related quality of life. J Chronic Dis 1987;40:593-603.
11. Torrance GW. Preferences for health states: a review of measurement methods. Mead Johnson Symp Perinat Dev Med 1982;20: 37-45.
12. Staquet MJ, Hayes RD, Fayers PM. Quality of Life Assessment in Clinical Trials, Methods and Practice. New York: Oxford University Press, 1998
13. Najman JM, Levine S. Evaluating the impact of medical care and technologies on the quality of life: a review and critique. Soc Sci Med 1981;15:107-115.
14. Nord E. Methods for quality adjustment of life years. Soc Sci Med 1992;34:559-569.
15. Sackett DL, Torrance GW. The utility of different health states as perceived by the general public. J Chronic Dis 1978;31:697-704.
16. Slevin ML, Stubbs L, Plant HJ et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 1990;300:1458-1460.
17. Horstmann GA Product of the month: SPSS statistical package for the sciences. Radiologe 1988;28:438-439.
18. Unic I, Stalmeier PF, Verhoef LC et al. Assessment of the time-tradeoff values for prophylactic mastectomy of women with a suspected genetic predisposition to breast cancer. Med Decis Making 1998;18:268-277.
19. Geller G, Bernhardt BA, Doksum T et al. Decision-making about breast cancer susceptibility testing: how similar are the attitudes of physicians, nurse practitioners, and at-risk women? J Clin Oncol 1998;16:2868-2876.
20. Epstein AM, Hall JA, Tognetti J et al. Using proxies to evaluate quality of life: can they provide valid information about patients' health status and satisfaction with medical care? Med Care 1989; 27:S91-98.
21. Hall J, Gerard K, Salkeld G et al. A cost utility analysis of mammography screening in Australia. Soc Sci Med 1992;34:993-1004.
22. Ashby J, O'Hanlon M, Buxton MJ. The time trade-off technique: how do the valuations of breast cancer patients compare to those of other groups? Qual Life Res 1994;3:257-265.
23. Hayman JA, Fairclough DL, Harris JR et al. Patient preferences concerning the trade-off between the risks and benefits of routine radiation therapy after conservative surgery for early-stage breast cancer. J Clin Oncol 1997;15:1252-1260.